Wegovy weight loss costs $500 a month — should we fund it?
"Every time I would go to the doctor, I would say 'Hey, I don't think it is normal. I'm quite overweight. Is there something that can help me?
"And the answer is always 'diet and exercise, diet and exercise', but I've always eaten well. I've always exercised, like, I lift weights at the gym."
A diagnosis at 29 for Polycystic Ovary Syndrome, which could impact weight due to insulin resistance and hormone imbalances, alluded to a possible cause.
Finally, in 2024, Rosie's GP prescribed her two weight loss medications over the last nine months. She lost 15kg but her progress on the current medication Saxenda plateaued and Rosie was still 15kg from her goal.
ADVERTISEMENT
That's why in July she is planning to transition to Wegovy. It is a weekly injectable weight loss medication with a celebrity aura that is available from July 1 in New Zealand after years of overseas success. It is also known as the diabetes medication Ozempic and reduces appetite while silencing food noise.
But Rosie, who works in retail with a side hustle to pay for her current weight loss medication, doesn't know if she can afford the potentially $500 monthly cost for Wegovy. While the medication is approved for use by Medsafe, it is not funded by Pharmac.
For those who are already using weight loss medication, Wegovy's availability is highly anticipated to decrease their weight further with fewer side effects. The fervent coverage on social media will no doubt attract more attention — and new converts — to medical weight loss.
Yet, Wegovy's high monthly cost and lack of government funding in New Zealand puts it out of reach for most people. The notion of funding weight loss drugs is stuck in a political tug-of-war between those who see obesity as a chronic health condition and those who blame obesity on a lack of personal responsibility. One in three New Zealanders over the age of 15 and one in 10 children are considered obese, the third highest amongst OECD countries.
Oprah Winfrey revealed in December 2023 that she had been using weight loss medication. (Source: Associated Press)
"...We haven't had really effective weight loss medications [in New Zealand] ever really so this is a real boost and it does change the dynamics a lot of obesity management," says Boyd Swinburn, a professor of population nutrition and global health at the University of Auckland.
Initially, the drug won't have a big impact because of its lack of affordability, but as other drug makers rush to make similar drugs, the cost will come down, he says.
ADVERTISEMENT
The challenge with getting funding for costly weight loss drugs like Wegovy is often shackled by "weight bias, the view that people's excess weight is their own silly fault...," says Swinburn.
"That kind of thinking, which really goes against the evidence of what's driving obesity here, that does carry into wider views about the deservedness of people with obesity having taxpayer-funded medications."
Swinburn pointed to our general acceptance of funding for other ongoing medications used to reduce blood pressure and high cholesterol as a model for how we should view weight loss medication.
The UK government has begun funding for Wegovy and the similar medication Mounjaro for some people and only for a two-year cycle for each patient, according to the BBC. The medication is costing the UK taxpayer close to US$7000 per person annually and there are concerns a fast roll-out could overwhelm the UK's National Health Service due to need. However, rising obesity rates could also "bankrupt" the NHS with the high cost of treating obesity-related diseases such as type 2 diabetes and cancer.
Novo Nordisk confirmed Wegovy's entry into the New Zealand market and said in a statement that it is in discussions with the New Zealand government to "explore options for broader, more equitable access for patients". The drug maker declined a request for an interview with one of its representatives.
Even without government funding in New Zealand, the cost of weight loss medications is essentially subsidised by the reduced grocery bills for patients, according to Dr Gerard McQuinlan, a Wellington-based GP specialising in weight loss. He is planning to transition most of his medical weight loss patients from Saxenda to Wegovy in the coming weeks.
"When they worked out how much they were spending on snacks and the foods they were used to — like high calorie, high carb foods and alcohol — it actually balances out the medication's cost.
ADVERTISEMENT
"They hardly go to a cafe because they're just not interested."
Long-term lifestyle change needed — Dave Letele
If Wegovy was quickly funded in New Zealand, former professional boxer and community health advocate Dave Letele would be irritated. He founded From the Couch, a 12-week programme that supports mostly Māori and Pasifika people towards a healthy lifestyle. Massey University's research on the programme showed participants lost on average 7kg during the programme with a significant reduction in signs of severe depression. The research suggested the programme was effective in "the holy grail" of weight loss programmes: long-term lifestyle change.
Community leader Dave Letele of BBM. (Source: 1News)
"It would be annoying if they funded [Wegovy] and not fund programmes like ours. We have a programme that breaks cycles for generations and we don't get much," says Letele, adding there is a waitlist to enter the From the Couch programme in some areas. A new location kicks off in Northland this week with funding from the Department of Internal Affairs.
'I'm not against the drug, like I'm not against the gastric sleeve [weight loss surgery]. Everything has its place, but there is so much more to it that you need to address.'
Letele stressed the need for wrap-around services including help with nutrition and fitness as well as psychological support.
ADVERTISEMENT
Wegovy might be a forever drug for some patients. Numerous studies show that many who stop taking it or similar medications regain much of their weight.
Dr Lara Courtenay, a weight loss physician at the MacMurray Centre in Auckland, has prepared many of her patients to transition from Saxenda to Wegovy throughout July. While Wegovy doesn't work for all patients, the weight loss is typically greater, the side effects are reduced and it requires one weekly injection whereas Saxender is injected daily.
Dr Lara Courtenay, a weight loss physician at the MacMurray Centre in Auckland. (Source: Breakfast)
Courtenay was a GP for seven years before transitioning to the medical weight loss field, describing it as "a very rewarding job". Along with weight loss medication, MacMurray Centre patients get the support of dieticians and psychologists to promote lifestyle change. This increases the possibility that they one day won't need regular weight loss medication, or require a reduced dose, says Courtenay.
However, whatever weight loss medication patients are on, once they stop, they face an uphill battle to prevent their body from returning to their set weight, which is their heaviest weight.
"What I say to patients is, 'you're a cave person, your cave person is trying to get you back to your set weight',' says Courtenay, 'and our bodies are really good at doing that.'
By Serena Solomon of rnz.co.nz
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
8 hours ago
- Scoop
Elective Boost To Get More Kiwis Out Of Pain
Minister of Health Thousands more New Zealanders will get the procedures they need faster, with the Government today announcing 21,000 more elective procedures over the next year through its Elective Boost programme, Health Minister Simeon Brown says. 'With over 215,000 procedures set to go ahead over the next year – over 21,000 more than previously planned – wait times will reduce, helping more Kiwis access life-changing operations like hip and knee replacements and cataract surgeries sooner. 'Our Government is focused on real delivery. For patients stuck on surgical waitlists, that means getting their procedures faster, no matter where they live or who provides it. 'We're making the health system work smarter, using both public hospitals and private providers in a coordinated national effort. New Zealanders don't care who does the operation – they just want it done and done quickly.' Many of the procedures will be delivered in Health New Zealand's dedicated elective facilities, including Manukau Health Park, Tōtara Haumaru on the North Shore, and Burwood Hospital in Christchurch. Others will be completed by private hospitals under new national agreements. The next phase of the Elective Boost follows strong early results: More than 12,764 procedures delivered to 1 June, outpacing the 10,579 target set for 30 June. The majority of procedures delivered have been for people waiting longer than four months for treatment. Statements of work issued to 60 private providers to deliver surgery at consistent national rates. 'We're taking a joined-up approach to procedure delivery. That means removing hold-ups, providing certainty, and unlocking capacity across the system,' Mr Brown says. 'This is how we start to fix the waitlist crisis that grew under the previous government. Too many Kiwis have been waiting in pain for procedures that could transform their lives – a tradie needing a shoulder operation to get back to work, a nana needing cataract surgery to see her grandkids clearly, or a child waiting months for tonsils to be removed. We're turning that around.' Mr Brown says the long-term goal is to treat 95 per cent of patients within four months by 2030 as part of the Government's health targets. 'Our Government is investing $30 billion a year in health, and we're backing that investment with a relentless focus on delivery. We are ramping up capacity in public hospitals, partnering with private providers in a more strategic way, and most importantly, we are getting Kiwis the care they need,' Mr Brown says. 'We've already delivered thousands of extra procedures through the Elective Boost, and now we're building on that with thousands more to put patients first.'
Scoop
a day ago
- Scoop
Greater Certainty For New Zealanders With Cancer
New Zealanders with cancer will have greater continuity of care from today, following Pharmac's decision on amending pharmaceutical schedule rules to allow access to new publicly funded cancer medicines in private hospitals and clinics. From 1 July 2025, when Pharmac funds a new cancer medicine or widens access to existing funded cancer medicines, eligible patients will be able to receive their medicine within private hospitals or clinics for a period of up to 12 months, without having to move their care to a public hospital. 'This decision will provide greater continuity of care for New Zealanders with cancer,' says Pharmac's Director Strategy, Policy and Performance, Michael Johnson. In the past, patients whose cancer medicines became publicly funded during their treatment found themselves having to transfer their treatment to a public hospital to access publicly funded medicines or else continue their private treatment and self-fund the costs. 'This change will allow these patients to benefit from newly funded cancer medicines, while maintaining their current treatment plans,' Johnson says. To be eligible, patients must already be receiving treatment at the date that their cancer medicine becomes funded by Pharmac, or have an approved treatment plan, and are about to start treatment at the date that their medicine becomes funded. This policy applies only to newly funded cancer medicines after 1 July 2025. To support the Government's decision to enable transitional access to publicly funded medicines in private settings, Pharmac consulted on rule changes to the pharmaceutical schedule between 26 May – 13 June 2025. 'While most people were supportive, we have listened to feedback and have decided to change the way we plan to implement this decision,' Johnson says. Pharmac initially proposed that private facilities would be able to obtain the funded medicine from public hospitals, as private hospitals are not currently able to make subsidy claims for cancer medicines. 'However, people told us this approach wouldn't work and would likely lead to patient safety risks due to double handling of medicines, process differences between public and private, and incompatibility of administration kits,' Johnson says. 'People told us they would prefer for private facilities to directly order cancer medicines and submit subsidy claims to Pharmac. We've listened to this feedback and have decided to change the way we plan to implement this decision,' Johnson says. Initially, Pharmac will work with private facilities to implement a direct payment arrangement for the cancer medicines that fall under this policy. Pharmac will in the future look to work with private facilities, Health NZ and suppliers to
RNZ News
a day ago
- RNZ News
Government urges Pharmac, Medsafe to embrace artificial intelligence
David Seymour said he saw AI playing a role in a more efficient Pharmac and Medsafe. Photo: RNZ / Mark Papalii The government has urged Pharmac and Medsafe to embrace artificial intelligence (AI) to speed up the approval of new medicines. Associate Health Minister David Seymour issued a statement on Tuesday, confirming he had recently written to the agencies, and that both had replied positively. "I believe that technology absorption greatly increases productivity and see Al playing a role in a more efficient Pharmac and Medsafe," he said. "Finding efficiencies in medicine assessment processes means patients can access the treatments they need faster." In response to Seymour's letter, Medsafe group manager Chris James acknowledged that AI, in future, could help streamline medicine decisions, speed up audits, and help analyse large information sets. A small number of staff were currently taking part in a Health Ministry pilot related to Microsoft's Copilot AI tool, he said. "We are also in the early stages of broader discussions about access to other AI tools with the ability to manage larger datasets and meet our commercial and patient sensitive confidentiality requirements," James said. In her response, Pharmac chair Paula Bennett said she greatly appreciated the minister's support and encouragement around the potential of AI. "I share your views that AI presents exciting opportunities to enhance productivity, improve processes, and deliver better outcomes for New Zealanders." She said staff were already using Microsoft Copilot "enthusiastically and creatively" to improve efficiency. "Staff have begun using AI tools to assist with tasks such as processing complex information, analysing large volumes of data, and improving the clarity and accessibility of technical content," Bennett said. "These applications are already helping us work more quickly and effectively and will also have a role in supporting greater transparency in our decision-making." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
